145 related articles for article (PubMed ID: 37263115)
1. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis.
Nishioka Y; Homma S; Ogura T; Sato S; Arai N; Tomii K; Kamio K; Sakamoto S; Miyazaki Y; Tomioka H; Hisata S; Handa T; Azuma A
Respir Investig; 2023 Jul; 61(4):498-507. PubMed ID: 37263115
[TBL] [Abstract][Full Text] [Related]
2. Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis.
Nishioka Y; Homma S; Okubo T; Azuma A
Contemp Clin Trials Commun; 2021 Sep; 23():100832. PubMed ID: 34471721
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
Taniguchi H; Kondoh Y; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sato A; Sugiyama Y; Kudoh S; Nukiwa T;
Respir Res; 2011 Jul; 12(1):93. PubMed ID: 21756364
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
14. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
15. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
16. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial.
West A; Chaudhuri N; Barczyk A; Wilsher ML; Hopkins P; Glaspole I; Corte TJ; Šterclová M; Veale A; Jassem E; Wijsenbeek MS; Grainge C; Piotrowski W; Raghu G; Shaffer ML; Nair D; Freeman L; Otto K; Montgomery AB
Thorax; 2023 Sep; 78(9):882-889. PubMed ID: 36948586
[TBL] [Abstract][Full Text] [Related]
17. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
18. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients.
Huang H; Dai HP; Kang J; Chen BY; Sun TY; Xu ZJ
Medicine (Baltimore); 2015 Oct; 94(42):e1600. PubMed ID: 26496265
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study.
Miedema JR; Moor CC; Veltkamp M; Baart S; Lie NSL; Grutters JC; Wijsenbeek MS; Mostard RLM
Respir Res; 2022 May; 23(1):139. PubMed ID: 35643466
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
